Among the documents was a January 2021 TGA report admitting that vaccine particles do not remain at the injection site, but disperse throughout the body – including the brain, liver and ovaries.
Australia’s Therapeutic Goods Administration (TGA) had reportedly been aware since 2021 that mRNA nanoparticles from the Wuhan coronavirus (COVID-19) injections could travel to vital organs.
Newly acquired documents as a consequence of a Freedom of Information Act request revealed this discovery, which was later presented by a British researcher. Among the documents was a January 2021 TGA report admitting that vaccine particles do not remain at the injection site, but disperse throughout the body – including the brain, liver and ovaries.
According to the TGA report, mRNA lipid nanoparticles were found in plasma and various organs such as the liver, adrenal glands, spleen and ovaries in rats injected with the Pfizer vaccine. The distribution of mRNA lipid nanoparticles was observed in multiple body locations including the eyes, heart, pituitary gland and pancreas. These findings were part of the study titled “Nonclinical Evaluation of BNT162b2 [mRNA] COVID-19 Vaccine (COMIRNATY),” which tracked the distribution of these particles in the body.
“Of course, the ovaries store and mature the ovum (female reproductive cells), so I’m not gonna pretend I’m not a little concerned about this, I’m more than a little concerned, actually,” John Campbell, an English YouTuber and retired nurse educator known for his videos about the COVID-19 pandemic, said about the implications for female reproductive health.
Another alarming section of the report highlighted a “slow but significant distribution of lipid nanoparticles from the site of injection with major uptake into the liver.”
“That means the mRNA could go into the vascular endothelial cells in the liver into the hepatocytes themselves, produce the spike protein that will be expressed, and there will be an inflammatory reaction against that spike protein in the liver,” Campbell added.
(Related: Study: Nearly two-thirds of COVID-19 vaccine recipients suffer from health complications a year later.)
Campbell then questioned how Australian health authorities could have known this in 2021 and still approved the vaccine.
“This is not what we were told,” he said. “How could the Australian health authorities know this back in 2021 and still approve this vaccine? Given that this was known, why were the vaccines given authorization when they were?”
Japanese study: Third dose of mRNA COVID-19 vaccine linked to significant increase in cancer mortality rates
This revelation is supported by a Japanese study published in the medical journal Cureus on April 8, which found a “statistically significant increase” in cancer deaths following the third mRNA-based COVID-19 vaccine dose.
The study examined age-adjusted mortality rates for 20 different types of cancer in Japan using official statistics on death, SARS-CoV-2 infections and vaccination rates from 2020 to 2022. Japan, boasting some of the highest vaccination rates globally, was administering its seventh vaccine dose at that time.
According to the study, there were no excessive cancer mortalities (-0.4 percent) during the initial year of the pandemic in 2020. However, a notable surge in cancer mortality coincided with the onset of mass vaccination campaigns in subsequent years.
The study found some excess cancer mortalities of 1.1 percent following the mass vaccination campaigns with the first and second doses in 2021, and then higher excess cancer mortalities of 2.1 percent in 2022 after the third vaccine dose rollout.
In 2022, the increase in excess mortality for all cancers became significant – but more so for leukemia (blood cancers) and those of the ovary, prostate, lip/mouth/throat, pancreas and breast. Breast cancer, which had a notable deficit in mortality rates in 2020, showed excess mortality in 2022 after the third dose, but certain cancers, like pancreatic cancer, displayed a steady rise predating the pandemic. But then, all six cancer types exceeded anticipated mortality values in 2021 and 2022.
The researchers argued that even with reduced cancer screenings and limited healthcare access during lockdowns, the increase in mortality rates is unexplainable due to the resolved restrictions on healthcare access for cancer screenings and treatments by 2022. Moreover, the study further highlights a concerning trend in mortality rates for the most fatal cancers – lung, colorectal, stomach and liver cancers. They were declining before the pandemic, but saw a decelerated rate of decline following the COVID-19 vaccine rollout.
The highest number of cancer-related mortalities occurred among individuals aged 80 to 84, with over 90 percent of this age group having received a third vaccine dose. Almost 100 percent of the vaccines administered were mRNA-based.
Follow PharmaceuticalFraud.com for more news on Big Pharma’s experimental vaccines.